A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the U.S. Food and Drug Administration (FDA) has approved QINLOCK™ (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for QINLOCK and reviewed the New Drug Application (NDA) under the Real-Time Oncology Review (RTOR) pilot program. The QINLOCK NDA is also part of Project Orbis, an initiative of the FDA Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology drugs among participating international health authorities. QINLOCK targets the broad spectrum of KIT and PDGFRα mutations known to drive GIST.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2020 and provided an update on clinical and corporate developments.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will have a reason to smile today, with the analysts making...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2019 and provided an update on clinical and corporate developments.
The analysts covering Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) delivered a dose of negativity to shareholders...
Deciphera (DCPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020.
It's shaping up to be a tough period for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), which a week ago released some...
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -15.93% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Deciphera stock popped Monday after the biotech gained FDA approval for a stomach cancer treatment. The drug, known by brand name Qinlock, treats gastrointestinal stromal tumors.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET. The conference will be held in a virtual meeting format.
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.25% and -97.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.
Deciphera Pharmaceuticals (NASDAQ: DCPH), a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -- about a 15% jump, thanks to good news from the U.S. Food and Drug Administration (FDA) regarding its drug ripretinib, marketed under the name Qinlock. First, the FDA approved Qinlock as the first fourth-line treatment for gastrointestinal stromal tumors (GISTs) and gave it Fast Track, Breakthrough Therapy, and Orphan Drug status.
Fund reveals 1st-quarter trades Continue reading...
DCPH earnings call for the period ending March 31, 2020.
Nomura analyst Christopher Marai maintained a Hold rating on Deciphera Pharmaceuticals (NASDAQ:DCPH) on Friday, setting a price target of $60, which is approximately 15.96% above the present share price of $51.74.